Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3099% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Gilead Sciences's price to sales ratio was 6.9× on Nov 11, 2026, against 5.4× a year earlier. Over the last 5 years it ranged from 2.7× to 7.0×, with a median of 3.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.9× | +1.7 |
| 2025 | Dec 31, 2025 | 5.2× | +1.2 |
| 2024 | Dec 31, 2024 | 4.1× | +0.4 |
| 2023 | Dec 29, 2023 | 3.7× | −0.3 |
| 2022 | Dec 30, 2022 | 4.0× | +0.7 |
| 2021 | Dec 31, 2021 | 3.3× | +0.2 |
| 2020 | Dec 31, 2020 | 3.2× | −0.5 |
| 2019 | Dec 31, 2019 | 3.7× | +0.0 |
| 2018 | Dec 31, 2018 | 3.6× | +0.2 |
| 2017 | Dec 29, 2017 | 3.4× | +0.4 |
| 2016 | Dec 30, 2016 | 3.0× | −1.7 |
| 2015 | Dec 31, 2015 | 4.7× | −2.2 |
| 2014 | Dec 31, 2014 | 6.9× | −3.9 |
| 2013 | Dec 31, 2013 | 10.8× | +4.8 |
| 2012 | Dec 31, 2012 | 6.0× | +2.2 |
| 2011 | Dec 30, 2011 | 3.8× | −0.1 |
| 2010 | Dec 31, 2010 | 3.9× | −2.2 |
| 2009 | Dec 31, 2009 | 6.1× | – |
See a number that looks wrong?